Chronic Heart Failure | Reduced Ejection Fraction | Treatment Algorithms | Claims Data Analysis | US | 2021
Treatment of heart failure with reduced ejection fraction (HFrEF) is well established with a wealth of evidence from clinical trials that supports the use of all standard-of-care therapies for CHF. ACE inhibitors or AIIRAs, beta blockers, and loop diuretics are used for the first-line treatment of HFrEF patients. Branded agents—Novartis’s Entresto and Amgen’s Corlanor—are also approved for use in this CHF subpopulation. However, calcium-channel blockers are contraindicated in this population. The HFrEF Treatment Algorithm offers insight into prescribing patterns in CHF subpopulations with relatively established treatment guidelines.
QUESTIONS ANSWERED
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed HF patients with reduced ejection fraction? What are the quarterly trends in prescribing among recently treated and newly diagnosed HFrEF patients?
- How have Amgen’s Corlanor and Novartis’s Entresto been integrated into the treatment algorithm for HFrEF?
- What proportion of HFrEF patients receive drug therapy within one year of diagnosis, and how quickly?
- What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of HFrEF patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated HFrEF patients?
Related Market Assessment Reports
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. Topical…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
